Amount of qualified clients: CDEC reviewed the uncertainty in the amount of patients with moderately extreme to severe hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical authorities consulted by CADTH indicated that some people who are labeled as obtaining gentle or moderate sickness may have a intense bleeding phenotype, whic